Loading...
XKRX
243070
Market cap208mUSD
Jul 10, Last price  
27,600.00KRW
1D
4.15%
1Q
6.77%
Jan 2017
-56.74%
IPO
-62.13%
Name

Huons Co Ltd

Chart & Performance

D1W1MN
XKRX:243070 chart
P/E
7.65
P/S
0.53
EPS
3,606.31
Div Yield, %
5.09%
Shrs. gr., 5y
1.81%
Rev. gr., 5y
8.83%
Revenues
620.77b
+5.17%
182,342,752,700168,966,126,192284,838,204,968328,595,382,423365,018,985,000406,677,881,000436,911,389,000492,386,811,000552,006,502,000590,231,060,000620,768,255,000
Net income
42.66b
+44.84%
20,932,846,67415,333,531,27435,069,393,80045,232,844,78138,206,911,00055,584,389,00030,752,119,00022,444,027,00050,472,995,00029,453,534,00042,660,591,000
CFO
45.01b
-14.37%
28,792,391,07228,920,689,28030,207,476,08820,882,911,66242,119,504,00046,506,244,00055,592,925,00035,390,881,00052,143,053,00052,558,668,00045,005,542,000
Dividend
Nov 24, 2025570 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Huons Co., Ltd. operates as a global healthcare company, providing a broad spectrum of medical solutions designed to enhance human health in South Korea and worldwide. Its extensive product line includes a variety of oral solid medications targeting numerous conditions, such as those affecting the circulatory and metabolic systems, pain and inflammation (antipyretic, analgesic, anti-inflammatory), musculoskeletal and digestive health, allergies (antihistamines), respiratory ailments, infections (antibiotics), and products for general well-being, urogenital issues, and various chemotherapeutic applications. The company also manufactures a comprehensive range of injectable pharmaceuticals. These span categories like anesthetics, pain and fever reducers, anti-inflammatory agents, muscle relaxants, antispasmodics, antihistamines, and treatments for circulatory and respiratory system disorders. Further offerings in this format include adrenocortical hormones, enzymes, minerals, solvents, calcium supplements, hemostatics, antidotes, antibiotics, metabolic aids, hyaluronic acid, wellness formulations, anticoagulants, and specialized products for tissue and cell systems. In addition to its pharmaceutical offerings, Huons provides ophthalmic solutions (eye drops), various biological products, and medical devices. Established in 1965 and headquartered in Seongnam, South Korea, the company was initially known as Kwang Myung Pharm before officially changing its name to Huons Co., Ltd. in June 2003.
IPO date
Jun 03, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT